Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Li Guangwei
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01159353CT.gov Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Insulin Aspart Protamine (this asset) | Li Guangwei | P3 | BB · 64 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Midazolam | Pfizer | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Insulin Aspart Protamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P3 | B · 60 |
| Cystic Fibrosis | — | P3 | CCC · 55 |
| Cirrhosis Of Liver | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Insulin Aspart Protamine in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/insulin-aspart-protamine-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →